Abstract:Abstract Background Drug repurposing has gained increased attention because it proposes to find effective cures for new diseases from approved drugs to lower development costs and time, and computational prediction of protein-ligand interactions (PLI) can provide accurate and fast drug screening. The shortcomings of existing machine learning-based methods for PLI prediction include 1) using human-selected features leads to loss of information and therefore lower accuracy and 2) using limited 3D structure data for input leads to lower generalizability. Methods To address the shortcomings, I proposed DeepLPI, a novel deep learning-based model that takes as input the raw sequences of drug molecules and proteins. DeepLPI applied pre-trained embedding models to encode the raw sequences into dense vector representations, which were then fed into 1D-CNN and biLSTM to obtain predictions. BindingDB dataset was used for model training and performance evaluation that is compared with a start-of-the-art method DeepCDA. Fig 1.Principle of NLP-inspired deep learning-based methods to embed drug SMILES strings (Mol2vec) and protein sequences (ProSE). Similar drugs or proteins will be in close distance after the embedding because these methods can capture contextual information.Fig 2.Model architecture from input to output of DeepLPI. Results Results showed that the DeepLPI reached an overall AUROC of 0.79 based on the BindingDB internal test, 76% better than DeepCDA. DeepLPI also outperformed DeepCDA using the external Davis dataset (AUROC=0.53) and COVID-19 3CL Protease dataset (AUROC=0.61). Figure 3.A randomly reserved part of the BindingDB dataset was grouped into four cases for testing, according to whether the drug molecules or the proteins are seen in the training set. (Note that the drug-target pairs in the test set are excluded from the training set.)Fig 4.We compare with DeepCDA, a recently published DTI prediction model that reported to be better than previous models. DeepLPI is 76% better in accuracy metric AUROC in classification tasks.Fig 5.As a preliminary attempt, the model trained on BindingDB was applied to a recent COVID-19 dataset targeting the 3CL-protease, which reported 897 small molecule drugs. Our model is better than the baseline method by 25%. Conclusion The high performance of DeepLPI suggests that our model has the potential to identify new COVID-19 drugs when applied to approved drugs. The generalizability of the model also promises applications to diseases in a wider scope. Disclosures All Authors: No reported disclosures.

Deep Learning Drives Efficient Discovery of Novel Antihypertensive Peptides from Soybean Protein Isolate

A Novel Machine Learning Strategy for the Prediction of Antihypertensive Peptides Derived from Food with High Efficiency

A Novel LSTM-Based Machine Learning Model for Predicting the Activity of Food Protein-Derived Antihypertensive Peptides.

Mining anti-hypertensive peptides in animal food through deep learning: a case study of gastrointestinal digestive products of royal jelly

A Deep Ensemble Predictor for Identifying Anti-Hypertensive Peptides Using Pretrained Protein Embedding

ACEiPP: A Deep Learning-Based Framework to Predict Angiotensin-Converting Enzyme (ACE)-Inhibitory Peptides Using High-Efficiency Amino Acid Descriptors

Sequence–Activity Relationship of Angiotensin-Converting Enzyme Inhibitory Peptides Derived from Food Proteins, Based on a New Deep Learning Model

Discovery of potential antidiabetic peptides using deep learning

Exploring novel ANGICon-EIPs through ameliorated peptidomics techniques: Can deep learning strategies as a core breakthrough in peptide structure and function prediction?

Predictive Modeling of Angiotensin I-Converting Enzyme Inhibitory Peptides Using Various Machine Learning Approaches.

Deep2Pep: A Deep Learning Method in Multi-label Classification of Bioactive Peptide

Virtual Screening for Angiotensin I-converting Enzyme Inhibitory Peptides from Phascolosoma Esculenta

Deep Learning-Based Bioactive Therapeutic Peptide Generation and Screening

Novel ACE Inhibitory Peptides Derived from Whey Protein Hydrolysates: Identification and Molecular Docking Analysis

Multi-dimensional deep learning drives efficient discovery of novel neuroprotective peptides from walnut protein isolates

“Bottom-Up” Strategy for the Identification of Novel Soybean Peptides with Angiotensin-Converting Enzyme Inhibitory Activity

Collaborative optimization and molecular docking exploration of novel ACE-inhibitory peptides from bovine milk by complex proteases hydrolysis

Novel Angiotensin-Converting Enzyme Inhibitory Peptides Derived from Oncorhynchus mykiss Nebulin: Virtual Screening and In Silico Molecular Docking Study.

519. DeepLPI: A Novel Drug Repurposing Model based on Ligand-Protein Interaction Using Deep Learning

Screening Milk-Derived Antihypertensive Peptides Using Quantitative Structure Activity Relationship (QSAR) Modelling and in Vitro/in Vivo Studies on Their Bioactivity

Screening of Novel Bioactive Peptides from Goat Casein: In Silico to In Vitro Validation